Lipid Molecule Erucamide Slows Retinal Degeneration by Activating Myeloid Immune Cells via TMEM19
核心洞察
Researchers at Scripps Research (搜索) identified erucamide (搜索), a naturally occurring fatty acid amide, as a key signaling molecule that declines sharply as photoreceptors degenerate in retinal disease.
Restoring erucamide (搜索) via porous silicon nanoparticles activated CD11b⁺ myeloid cells through the TMEM19 (搜索) receptor, preserving neurovascular architecture rather than targeting photoreceptors directly.
The study, published in Nature Neuroscience, demonstrated slowed tissue breakdown in preclinical models, offering a potential new therapeutic pathway for diabetic retinopathy (搜索), retinitis pigmentosa (搜索), and age-related macular degeneration (搜索).
A team at Scripps Research (搜索), in collaboration with UC San Diego (搜索) and the Lowy Medical Research Institute (搜索), has discovered that a naturally occurring lipid molecule called erucamide (搜索) acts as a critical coordinator of the retina's protective response to injury. Their study, published in Nature Neuroscience on June 19, 2026, reveals that erucamide levels drop precipitously as light-sensing photoreceptors degenerate, and that restoring the molecule can slow retinal tissue breakdown by engaging the immune system rather than targeting photoreceptors directly.
"The retina doesn't simply deteriorate; in fact, it actively responds to injury," said senior author Martin Friedlander, a professor at Scripps Research (搜索). "Our work identifies erucamide (搜索) as a signaling molecule that helps coordinate that response."
An Unbiased Metabolomics Screen Identifies a Key Signal
The retina depends on constant communication between neurons, glia, blood vessels, and immune cells—a system known as the neurovascular unit. In diseases such as diabetic retinopathy (搜索), retinitis pigmentosa (搜索), and age-related macular degeneration (搜索), this coordination breaks down, photoreceptors die, and vision fades.
Building on earlier observations that transplanted stem cell-derived retinal cells could slow degeneration long after the cells had disappeared, the team hypothesized that protective molecular signals were being released. To identify these signals, the scientists employed mass spectrometry-based metabolomics across several well-established preclinical models of retinal degeneration, searching for molecules whose levels changed as disease progressed.
Among the many molecules detected, erucamide (搜索)—a 22:1 monounsaturated omega-9 fatty acid amide—stood out. Its levels fell sharply as photoreceptors began to deteriorate. "That was a pivotal moment for us," recalled co-author Dale Boger, the Richard and Alice Cramer Professor of Chemistry at Scripps Research (搜索). "It raised the possibility that erucamide could be influencing how tissue responds and wasn't just changing as a consequence of disease."
Nanoparticle Delivery Overcomes Hydrophobicity Challenge
Because erucamide (搜索) is hydrophobic and prone to clumping in water-based mediums, the team utilized porous silicon nanoparticles—engineered delivery vehicles designed to release molecules in a controlled manner—to achieve stable, uniform distribution within the eye. This formulation approach was essential, as most ophthalmic medicines are water-based.
TMEM19 (搜索): The Molecular Gateway for Myeloid Cell Activation
Rather than acting directly on photoreceptors, erucamide (搜索) was found to activate CD11b⁺ myeloid cells, a population of immune cells in the retina that respond to injury and support tissue health. Critically, the team identified TMEM19 (搜索) as the binding protein for erucamide. Genetic or structural reduction of TMEM19 completely halted erucamide's protective efficacy, confirming it as the primary molecular gateway for the signaling pathway.
Once stimulated through TMEM19 (搜索), myeloid cells released angiogenic and neurotrophic cytokines that supported both nerve cells and the blood vessels that nourish them. While the effect was not an outright reversal of retinal damage, it slowed aspects of degeneration by preserving the structure and function of remaining tissue.
"Instead of targeting the photoreceptors themselves, erucamide (搜索) appears to work by engaging the surrounding environment," explained first author Guoqin Wei, a staff scientist at Scripps Research (搜索) who began the project as a postdoctoral research associate in Friedlander's lab seven years earlier. "That shift in perspective could be important for treating degenerative retinal diseases going forward."
Broad Therapeutic Implications and Future Directions
The findings point to a strategy with potential relevance across multiple progressive blinding diseases, including diabetic retinopathy (搜索), retinitis pigmentosa (搜索), and age-related macular degeneration (搜索). By targeting foundational tissue degeneration mechanics rather than a single disease pathway, the approach may offer broad clinical applicability.
However, additional studies are needed to clarify the full signaling pathway. Future work will focus on erucamide (搜索) signaling in various retinal diseases and whether targeting this pathway can provide meaningful benefits over time. The team also plans to test modified versions of erucamide to determine whether they produce stronger or more stable effects, while investigating whether related lipid molecules may be even more effective at activating protective responses.
"The goal is to reinforce a signal that's already present," noted Friedlander. "If we can learn how to modulate that response carefully, it could offer a new path for slowing the progression of retinal diseases where treatment options remain limited."
The study was supported by funding from the Lowy Medical Research Institute (搜索), the National Eye Institute (grants R01EY11254 and 5R24EY017540), the California Institute for Regenerative Medicine (grant TR1-01219), the National Science Foundation, the National Institutes of Health, the National Institute on Drug Abuse, and the Natural Sciences and Engineering Research Council of Canada.